Fellow of The Academy of Medical Sciences, United Kingdom
The scientist’s investigation covers issues in COPD, Internal medicine, Physical therapy, Spirometry and Exacerbation. Jørgen Vestbo mostly deals with Obstructive lung disease in his studies of COPD. He combines subjects such as Placebo and Surgery with his study of Internal medicine.
The study incorporates disciplines such as Smoking cessation, Cohort study, Disease, Severity of illness and Comorbidity in addition to Physical therapy. Jørgen Vestbo has included themes like C-reactive protein, Pulmonary function testing, Bronchiectasis and Cardiology in his Spirometry study. His Exacerbation research includes elements of Bronchodilator and Pediatrics.
His primary scientific interests are in COPD, Internal medicine, Physical therapy, Intensive care medicine and Pulmonary disease. His COPD study incorporates themes from Exacerbation, Spirometry, Asthma, Severity of illness and Cohort. The Spirometry study combines topics in areas such as Pulmonary function testing and FEV1/FVC ratio.
His work in Internal medicine addresses subjects such as Surgery, which are connected to disciplines such as Respiratory disease. Jørgen Vestbo interconnects Epidemiology, Population study, Obstructive lung disease, Disease and Comorbidity in the investigation of issues within Physical therapy. His study in Fluticasone propionate is interdisciplinary in nature, drawing from both Placebo and Salmeterol.
Jørgen Vestbo spends much of his time researching COPD, Internal medicine, Intensive care medicine, Pulmonary disease and Exacerbation. His COPD study focuses on Obstructive lung disease in particular. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Cardiology.
His study looks at the intersection of Intensive care medicine and topics like Clinical trial with Coronavirus disease 2019. Within one scientific family, Jørgen Vestbo focuses on topics pertaining to Pharmacotherapy under Pulmonary disease, and may sometimes address concerns connected to Inhalation. Jørgen Vestbo has researched Exacerbation in several fields, including Pneumonia, Prednisolone, Rate ratio, Respiratory system and Indacaterol.
His primary areas of investigation include COPD, Internal medicine, Pulmonary disease, Exacerbation and Asthma. Jørgen Vestbo does research in COPD, focusing on Obstructive lung disease specifically. His work in the fields of Randomized controlled trial, FEV1/FVC ratio and Pneumonia overlaps with other areas such as In patient.
His Pulmonary disease research includes themes of Inhaled corticosteroids, Disease progression and Cigarette smoking. The Exacerbation study which covers Gastroenterology that intersects with Risk of mortality, Fibrinogen, Confounding, Indacaterol and Beclometasone dipropionate. His work carried out in the field of Asthma brings together such families of science as Respiratory disease, Genome-wide association study, Allergy and Environmental health.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Jørgen Vestbo;Suzanne S. Hurd;Alvar G. Agustí;Paul W. Jones.
American Journal of Respiratory and Critical Care Medicine (2007)
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
B. R. Celli;W. MacNee;A. Agusti;Antonio R Anzueto.
European Respiratory Journal (2004)
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson;Bartolome Celli;Gary T. Ferguson;Christine Jenkins.
The New England Journal of Medicine (2007)
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
Claus F. Vogelmeier;Gerard J. Criner;Fernando J. Martinez;Antonio Anzueto.
American Journal of Respiratory and Critical Care Medicine (2017)
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst;Jørgen Vestbo;Jørgen Vestbo;Antonio Anzueto;Nicholas Locantore.
The New England Journal of Medicine (2010)
Chronic obstructive pulmonary disease.
Peter J. Barnes;Peter G. J. Burney;Edwin K. Silverman;Bartolome R. Celli.
Nature Reviews Disease Primers (2015)
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Peter Calverley;Romain Pauwels;Jørgen Vestbo;Paul Jones.
The Lancet (2003)
A 15-year follow-up study of ventilatory function in adults with asthma.
Peter Lange;Jan Parner;Jørgen Vestbo;Peter Schnohr.
The New England Journal of Medicine (1998)
Prognostic value of nutritional status in chronic obstructive pulmonary disease
Charlotte Landbo;Eva Prescott;Peter Lange;Jørgen Vestbo.
American Journal of Respiratory and Critical Care Medicine (1999)
Characterisation of COPD heterogeneity in the ECLIPSE cohort
Àlvar Agustí;Peter Ma Calverley;Bartolome R Celli;Harvey O Coxson.
Respiratory Research (2010)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: